Transforming a human enzyme to break down toxic chemicals
Official title: Converting human butyrylcholinesterase into a metalloenzyme for catalytic hydrolysis of organophosphates
Funded at University of California Los Angeles · NIH-10928701 · Data updated 2026-11-12
This study is looking at ways to make a special enzyme better at breaking down harmful chemicals found in pesticides and nerve agents, so it can help people who have been exposed to these toxins feel safer and healthier.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $192,331 |
| NIH project number | 5R21NS126163-02 |
| Project ID | NIH-10928701 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include military personnel and civilians who may be at risk of exposure to organophosphate toxins.
✕Less likely to help
Patients who have not been exposed to organophosphate compounds or those with unrelated health conditions may not benefit from this research.
What this research studies
This research focuses on modifying the human enzyme butyrylcholinesterase (BChE) to enhance its ability to break down toxic organophosphate compounds, which are harmful chemicals found in pesticides and nerve agents. By introducing specific mutations and using oxime compounds, the goal is to create a more effective therapeutic enzyme that can degrade these toxins in the bloodstream. This approach aims to improve the enzyme's effectiveness while minimizing potential side effects, making it a safer option for patients exposed to these harmful substances.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for individuals exposed to toxic organophosphate compounds, potentially saving lives and reducing long-term health effects.
How similar studies have gone: Previous research has shown promise in modifying enzymes for enhanced catalytic activity, indicating that this approach may lead to successful outcomes.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Shafaat, Hannah S — University of California Los Angeles
- Study coordinator: Shafaat, Hannah S
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genetic changes in blood cells relate to heart disease in people with HIV
A study will look at how age-related blood cell mutations and large chromosomal changes might contribute to heart disease risk in people living with HIV.
-
Systems genetics of vascular smooth muscle phenotypes in heart disease
Aims to understand how genetic differences influence vascular smooth muscle cells to improve prevention and treatment of coronary artery disease.
-
Motivation for Alcohol Use in Humans and How It Can Be Measured
This grant explores how people are motivated to drink alcohol and tests a safe, controlled way to study that motivation to inform better treatments for alcohol use disorder.
-
Overcoming CAR T cell resistance with tumor-targeted IL-12 to boost anti-tumor immunity
Aims to make CAR T cell therapy work better for solid tumors by using tumor-focused IL-12 to boost the body’s attack on cancer.
-
PediCODE: A Biorepository and Consortium for CoDE - Congenital Diarrhea and Enteropathy
A nationwide effort to collect clinical data and patient-derived samples to uncover the genetic causes of congenital diarrhea and enteropathy and to build a resource that helps researchers study these diseases.
-
Mentor Moms+: a community-led plan to cut alcohol use and HIV risk during pregnancy in South Africa
A community-based program adapts a trusted peer-led model to help pregnant and lactating people reduce alcohol use and HIV risk in South Africa.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.